|
|
|
|
true
10000
-
Growing breast cancer stem cells to get at the tumor’s root
Dr. Robert Oshima and colleagues developed a technique for growing cancer stem cells—an advance that will help them search for new approaches to preventing breast tumor recurrence.
-
Meet a cancer researcher
Meet Dr. Jochen Maurer, a postdoctoral researcher in Sanford-Burnham’s NCI-designated Cancer Center.
-
Personalized models of childhood brain cancer
Dr. Robert Wechsler-Reya and his team created a new mouse model for a particularly malignant form of medulloblastoma, and zero in on a potential therapy.
|
|
Studying tumor development
The goals of the Tumor Development Program are to identify the molecular mechanisms that control proliferation, differentiation, and survival during normal development, to investigate how dysregulation of these mechanisms contributes to tumor initiation and progression, and to use this information to develop more effective approaches to treating human cancers. The program integrates scientists with expertise in developmental biology and stem cell biology with investigators focusing on cell cycle regulation, DNA damage repair, and epigenetic regulation of gene expression.
|
|
Scientists in the Tumor Development Program discovered a novel mechanism driving cancer. Some tumors develop after genetic and epigenetic alterations in certain genes (“mutator genes”), resulting in genomic instability and the rapid accumulation of mutations in many cancer genes that drive tumorigenesis. Research on genetic instability has provided a better understanding of tumor development and progression, and has already yielded useful clinical tests for diagnosis of hereditary cancer families and for cancer prognosis.
How our research helps improve health
Already, discoveries by scientists in this program have resulted in a synthetic vitamin A-like drug (retinoid) that is approved for treatment of some types of cancer. Genetically engineered mouse strains have been created by program scientists to serve as models for studying the origins of breast cancer and for testing new therapies to treat it.
Understanding how the genetic and epigenetic changes in cancer arise, the gene targets of such changes and the consequences of inappropriate gene regulation can reveal new strategies for drug discovery or suggest optimal approaches for treating individual patients.
Research - Cancer - Tumor Development: How Our Research Helps |
|
|
-
TD-60 is required for interphase cell cycle progression.
Yenjerla M, Panopoulos A, Reynaud C, Fotedar R, Margolis RL.
Cell Cycle. 2013 Mar 1;12(5):837-41. doi: 10.4161/cc.23821. Epub 2013 Feb 6.
Read More
-
Guidelines for the use and interpretation of assays for monitoring autophagy.
Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL...
Autophagy. 2012 Apr;8(4):445-544.
Read More
-
Reversal by RARα agonist Am580 of c-Myc-induced imbalance in RARα/RARγ expression during MMTV-Myc tumorigenesis.
Bosch A, Bertran SP, Lu Y, Garcia A, Jones AM, Dawson MI, Farias EF.
Breast Cancer Res. 2012 Aug 24;14(4):R121. [Epub ahead of print]
Read More
-
Endogenous renovascular hypertension combined with low shear stress induces plaque rupture in apolipoprotein E-deficient mice.
Jin SX, Shen LH, Nie P, Yuan W, Hu LH, Li DD, Chen XJ, Zhang XK, He B.
Arterioscler Thromb Vasc Biol. 2012 Oct;32(10):2372-9. doi: 10.1161/ATVBAHA.111.236158. Epub 2012 Aug 16.
Read More
-
HNF4α antagonists discovered by a high-throughput screen for modulators of the human insulin promoter.
Kiselyuk A, Lee SH, Farber-Katz S, Zhang M, Athavankar S, Cohen T, Pinkerton AB, Ye M, Bushway P, Richardson AD, Hostetler HA, Rodriguez-Lee M, Huang L, Spangler B, Smith L, Higginbotham J, Cashman J, Freeze H, Itkin-Ansari P, Dawson MI, Schroeder F, Cang Y, Mercola M, Levine F.
Chem Biol. 2012 Jul 27;19(7):806-18. doi: 10.1016/j.chembiol.2012.05.014.
Read More
-
Subgroup-specific structural variation across 1,000 medulloblastoma genomes.
Northcott PA, Shih DJ, Peacock J, Garzia L, Morrissy AS, Zichner T, Stütz AM, Korshunov A, Reimand J, Schumacher SE, Beroukhim R, Ellison DW, Marshall CR, Lionel AC, Mack S, Dubuc A, Yao Y, Ramaswamy V, Luu B, Rolider A...
Nature. 2012 Aug 2;488(7409):49-56. doi: 10.1038/nature11327.
Read More
View All Publications
Research - Cancer - Tumor Development: Recent Publications |
|
HNF4α antagonists discovered by a high-throughput screen for modulators of the human insulin promoter.
Kiselyuk A, Lee SH, Farber-Katz S, Zhang M, Athavankar S, Cohen T, Pinkerton AB, Ye M, Bushway P, Richardson AD, Hostetler HA, Rodriguez-Lee M, Huang L, Spangler B, Smith L, Higginbotham J, Cashman J, Freeze H, Itkin-Ansari P, Dawson MI, Schroeder F, Cang Y, Mercola M, Levine F
Chem Biol. 2012 Jul 27;19(7):806-18
Transcription factors ETS2 and MESP1 transdifferentiate human dermal fibroblasts into cardiac progenitors.
Islas JF, Liu Y, Weng KC, Robertson MJ, Zhang S, Prejusa A, Harger J, Tikhomirova D, Chopra M, Iyer D, Mercola M, Oshima RG, Willerson JT, Potaman VN, Schwartz RJ
Proc Natl Acad Sci U S A. 2012 Aug 7;109(32):13016-21
Antagonist effect of triptolide on AKT activation by truncated retinoid X receptor-alpha.
Lu N, Liu J, Liu J, Zhang C, Jiang F, Wu H, Chen L, Zeng W, Cao X, Yan T, Wang G, Zhou H, Lin B, Yan X, Zhang XK, Zeng JZ
PLoS One. 2012;7(4):e35722
An animal model of MYC-driven medulloblastoma.
Pei Y, Moore CE, Wang J, Tewari AK, Eroshkin A, Cho YJ, Witt H, Korshunov A, Read TA, Sun JL, Schmitt EM, Miller CR, Buckley AF, McLendon RE, Westbrook TF, Northcott PA, Taylor MD, Pfister SM, Febbo PG, Wechsler-Reya RJ
Cancer Cell. 2012 Feb 14;21(2):155-67
View All Publications
|
|
Global - Left Nav: Bottom Blue Border
|
|
|
|
|
|